Home › NCT05174351

Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction

Effect of Beta-blocker Discontinuation on Functional Capacity and Cardiac Hemodynamics in Patients With Heart Failure With Preserved Ejection Fraction

Who can join

Ages 50 to 80 · All sexes

Inclusion Criteria:

* Stable HFpEF patients with NYHA Class II-III or elevated BNP ≥100
* N=30 (Target: 30).
* Age: 50 \~ 80 years.
* ECHO evidence of EF ≥50% and Grade 2 or 3 diastolic dysfunction.
* Chronic loop diuretic use
* Currently on beta-blocker

Exclusion Criteria:

* Beta blocker was prescribed for treating other cardiac conditions such as atrial fibrillation or coronary artery disease.
* Heart rate \> 100 bpm
* Recent hospitalization due to HF within 3 months
* Non-English speaker

About the study

This is a prospective pilot study to evaluate changes before and 4 weeks after beta-blocker withdrawal in 30 HFpEF patients.

What is being tested

• beta blocker discontinuation (other)

Sponsor: UConn Health · Participants: 30 · Started: Dec 20, 2021

Contact the study team

• Kai Chen, MD,PhD · Phone: 860-679-3343

Official record on ClinicalTrials.gov — NCT05174351

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.